Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ONXEO. We currently have 5 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Multiple events in 2017
06 Jan 17
The major near-term catalyst for Onxeo will likely be the Livatag Phase III data in second-line liver cancer, which is expected around mid-2017. During 2017 we also expect new asset AsiDNA to advance into clinical testing, and progress with Beleodaq (belinostat), which could start the regulatory required Phase III trial. Onxeo is increasingly focused on exploring further opportunities for these assets, and has a number of preclinical collaborations ongoing. While data from these early-stage studies are not likely to be a major share price driver, in the longer term, these efforts could help to maximise value. Onxeo recently raised €12.5m to help fund these programmes. Our updated valuation is €350m.
Key catalyst approaching
23 Aug 16
With its H116 results, Onxeo reported that R&D is progressing according to plan. Preliminary data from the Phase III ReLive trial with Livatag are due around mid-2017, which is the main catalyst in the next 12 months. Update on the newly acquired DNA repair asset, AsiDNA, revealed that the project could enter the clinic already next year. Although sales of Onxeo’s third product Beleodaq somewhat lagged our expectations, H116 operating costs were managed well, suggesting that the key catalysts are achievable with current cash.
Acquisition expands clinical pipeline
02 Jun 16
With its acquisition of DNA Therapeutics, Onxeo has added a clinical stage signal-interfering DNA (siDNA) technology, which has already been tested in a Phase I trial for melanoma and demonstrated an attractive safety profile and preliminary anti-tumour activity, when administered locally. The new product called AsiDNA is a first-in-class and differentiated asset in the up-and-coming DNA repair interference field. Our increased valuation of Onxeo is €343m.
BelCHOP data at ASH ahead of Phase III start
22 Dec 15
With Phase I data confirming the existing safety profile from the BelCHOP (Beleodaq with CHOP) study in the treatment of frontline PTCL, the path is now clear for initiation of the planned Phase III trial during H116 with partner Spectrum. Beleodaq is one of a trio of orphan oncology assets under development at Onxeo, also including Livatag (liver cancer), which has now completed seven safety reviews, and Validive (oral mucositis arising from chemoradiotherapy). New preclinical collaborations for Livatag and Beleodaq could further expand the potential of both.
LA VIE est BELle (LivAtag, ValidIvE, BELeodaq)
08 Sep 15
The next major value inflection point for Onxeo will likely be availability of Phase III Livatag data for second-line liver cancer expected H117. This product could potentially be the first launched by Onxeo in Europe as part of the orphan oncology strategy. Prior to Livatag data, progression with Beleodaq and Validive is expected, with the start of further Phase III trials anticipated in H116. Our valuation, which is largely unchanged at €328m, suggests the current share price is ascribing limited value to these assets.
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.